Nouara Yahi

Marseille, 13015, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 51 publications

An Optimal Spray Device for the Nose-to-Brain Delivery of AmyP53, an Adaptive Therapeutic Peptide for Alzheimer's and Parkinson's Diseases.

An Optimal Spray Device for the Nose-to-Brain Delivery of AmyP53, an Adaptive Therapeutic Peptide for Alzheimer's and Parkinson's Diseases.

Journal: Pharmaceutics
Published: July 01, 2026

From Meteorites to Membrane Rafts: Ganglioside-Incorporating Prebiotic Vesicles and the Emergence of Membrane Domain Organization.

From Meteorites to Membrane Rafts: Ganglioside-Incorporating Prebiotic Vesicles and the Emergence of Membrane Domain Organization.

Journal: The Journal of membrane biology
Published: June 08, 2026

Serotonergic Signaling Rewired: A Lipid Raft-Controlled Model of Synaptic Transmission Grounded in the Fundamental Parameters of Biological Systems.

Serotonergic Signaling Rewired: A Lipid Raft-Controlled Model of Synaptic Transmission Grounded in the Fundamental Parameters of Biological Systems.

Journal: Life (Basel, Switzerland)
Published: December 19, 2025

The Enigmatic Conserved Q134-F135-N137 Triad in SARS-CoV-2 Spike Protein: A Conformational Transducer?

The Enigmatic Conserved Q134-F135-N137 Triad in SARS-CoV-2 Spike Protein: A Conformational Transducer?

Journal: Biomolecules
Published: December 12, 2025

Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.

Correction: Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.

Journal: Scientific reports
Published: July 03, 2025

Targeting gangliosides to treat Alzheimer's and Parkinson's diseases: A disruptive approach with the first-in-class peptide AmyP53.

Targeting gangliosides to treat Alzheimer's and Parkinson's diseases: A disruptive approach with the first-in-class peptide AmyP53.

Journal: Neural regeneration research
Published: January 14, 2025

Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.

Preclinical assessment of a ganglioside-targeted therapy for Parkinson's disease with the first-in-class adaptive peptide AmyP53.

Journal: Scientific reports
Published: October 22, 2024

Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrow.

Conformationally adaptive therapeutic peptides for diseases caused by intrinsically disordered proteins (IDPs). New paradigm for drug discovery: Target the target, not the arrow.

Journal: Pharmacology & therapeutics
Published: September 01, 2024

Glutamate, Gangliosides, and the Synapse: Electrostatics at Work in the Brain.

Glutamate, Gangliosides, and the Synapse: Electrostatics at Work in the Brain.

Journal: International journal of molecular sciences
Published: July 18, 2024

Cholesterol-Dependent Serotonin Insertion Controlled by Gangliosides in Model Lipid Membranes.

Cholesterol-Dependent Serotonin Insertion Controlled by Gangliosides in Model Lipid Membranes.

Journal: International journal of molecular sciences
Published: July 13, 2024

Host Membranes as Drivers of Virus Evolution.

Host Membranes as Drivers of Virus Evolution.

Journal: Viruses
Published: July 31, 2023

Structure of the Myelin Sheath Proteolipid Plasmolipin (PLLP) in a Ganglioside-Containing Lipid Raft.

Structure of the Myelin Sheath Proteolipid Plasmolipin (PLLP) in a Ganglioside-Containing Lipid Raft.

Journal: Frontiers in bioscience (Landmark edition)
Published: March 21, 2023
Showing 1-12 of 51

Last Updated: 09/26/2026